Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.44 USD
+0.03 (0.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.44 USD
+0.03 (0.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Biogen (BIIB) Board Okays Hemophilia Business Spin-off
by Zacks Equity Research
Biogen (BIIB) announced that its board of directors has approved the spin-off of its hemophilia business into a new company Bioverativ Inc.
Sarepta's (SRPT) Application for DMD Drug Accepted in the EU
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization application (MAA) for Exondys 51.
Conatus Stock Up on Liver Drug Collaboration with Novartis
by Zacks Equity Research
Conatus (CNAT) inked an exclusive option, collaboration and license agreement with Novartis (NVS) for the worldwide development and commercialization of emricasan.
Agios Stops Development of PKR Activator AG-519, Stock Falls
by Zacks Equity Research
Shares of Agios (AGIO) tanked 19.4% after the company decided to discontinue the development of its PKR activator, AG-519.
Ionis (IONS) Receives Milestone Payment from AstraZeneca
by Zacks Equity Research
Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.
Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis
by Zacks Equity Research
Incyte (INCY) and Eli Lilly (LLY) announced that the EMA's CHMP has issued a positive opinion for the approval of Olumiant (baricitinib).
Roche (RHHBY) to Terminate Pacifica Bioscience Agreement
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.
Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls
by Zacks Equity Research
Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.
Intercept (ICPT) Ocaliva Gains Conditional Approval in EU
by Zacks Equity Research
Intercept (ICPT) Ocaliva, in combination with UDCA, was approved in the EU for the treatment of PBC.
Trovagene to Focus More on Liquid Biopsy Testing Market
by Zacks Equity Research
Trovagene, Inc. (TROV), recently announced that it will increase its focus on the global distribution of kits and systems to clinical research laboratories for the liquid biopsy oncology testing market.
athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017
by Zacks Equity Research
athenahealth Inc. (ATHN) reaffirmed its full-year 2016 guidance and issued a stable guidance for 2017.
Intuitive Surgical (ISRG) Raises Share Buyback to $3 Billion
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) increased the authorized amount available under the company's share repurchase program to $3.0 billion.
Envision Healthcare Acquires Desert Mountain Consultants
by Zacks Equity Research
Envision Healthcare Corporation (EVHC), a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced the acquisition of Desert Mountain Consultants in Anesthesia, Inc.
Proteon Slips to 52-Week Low on Kidney Disease Study Data
by Zacks Equity Research
Proteon's (PRTO) shares hit a 52-week low after reporting poor top-line phase III data on vonapanitase in patients with chronic kidney disease.
Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe
by Zacks Equity Research
Alexion's (ALXN) shares plunged after the company's board of directors announced new leadership appointments.
Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval
by Zacks Equity Research
Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.
Corcept Korlym Positive in Phase I/II Breast Cancer Study
by Zacks Equity Research
Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.
Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails
by Zacks Equity Research
Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.
AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting
by Zacks Equity Research
AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.
Sage Therapeutics Stock Up on SAGE-547 Regulatory Update
by Zacks Equity Research
Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.
Theravance Stock Up on Fast Track Status for Velusetrag
by Zacks Equity Research
Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.
Bristol-Myers Reports Data from Opdivo Combination Studies
by Zacks Equity Research
Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.
GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss
by Zacks Equity Research
GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).
Novo Nordisk Files Regulatory Application for Semaglutide
by Zacks Equity Research
Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.
Acceleron, Celgene Present Myelodysplastic Syndromes Data
by Zacks Equity Research
Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.